Eli Lilly and Company has concluded the acquisition of biopharmaceutical company Morphic Holding at $57 per share, a strategic move aimed at bolstering its inflammatory bowel disease (IBD) portfolio.

The early trial of TERN-601 is encouraging, but I wouldn't buy shares of the stock just yet. It's still far too early in the ...

Eli Lilly is acquisitive, too, and just purchased a company called Morphic Holding ... Eli Lilly looks like a great stock to buy and hold for the long run, while its top-notch track record ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.06% and ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from TD Cowen maintained a Buy rating on the stock and ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

The maintained Buy rating and price target signal confidence in Eli Lilly's continued growth and ... The company has also completed the acquisition of Morphic Holding (NASDAQ:MORF), Inc., adding ...

Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,025.00. The company’s shares closed last Friday at $922.12.

After a period of rating suspensions, Citi resumed its coverage on Eli Lilly (NYSE:LLY) with a buy recommendation and a $1,060 price target, citing the company’s GLP-1 pipeline, including its ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".